The iTind Device Receives FDA de Novo Classification Order for Benign Prostatic Hyperplasia (BPH) Non-Surgical Treatment DeviceExclusive Olympus Partnership with Israeli Medi-Tate Will Bring Novel BPH Treatment to U.S. Market
April 6, 2020
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA De Novo classification of the iTind device, a non-surgical device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH). The iTind device was developed by the Israeli-based medical device manufacturer Medi-Tate. Through an investment in Medi-Tate, Olympus holds the exclusive right to distribute Medi-Tate products in the U.S., including the iTind device. This strategic investment, and the introduction to the U.S. market of this novel device, strengthens the already robust Olympus urology portfolio by offering expanded options in enhanced patient care.
Press releases are company announcements that are directed at the news media.
Information posted on this site is current and accurate only at the time of their original publication date, and may now be outdated or inaccurate.